Seattle Genetics traded at $138.99 this Friday May 27th, increasing $0.53 or 0.38 percent since the previous trading session. Looking back, over the last four weeks, Seattle Genetics gained 6.55 percent. Over the last 12 months, its price fell by 8.01 percent. Looking ahead, we forecast Seattle Genetics to be priced at 137.82 by the end of this quarter and at 127.86 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
138.99
Daily Change
0.38%
Yearly
-8.01%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,761.00 -1.00 -0.03% -1.29%
Astellas Pharma 2,025.50 -10.50 -0.52% 16.14%
Eisai 5,298.00 26.00 0.49% -26.71%
Daiichi Sankyo 3,440.00 -22.00 -0.64% 36.97%
AbbVie 150.01 -0.56 -0.37% 32.52%
Acadia Pharmaceuticals 16.56 0.33 2.03% -25.87%
Agios Pharmaceuticals 19.67 0.28 1.44% -64.74%
Amgen 255.19 2.14 0.84% 7.25%
Bayer 66.49 0.59 0.90% 27.28%
Biogen 206.06 1.84 0.90% -22.96%
Bluebird Bio 3.23 0.07 2.06% -89.64%
BioMarin Pharmaceutical 80.83 1.97 2.50% 4.57%
Bristol-Myers Squibb 76.14 -1.45 -1.87% 15.86%
Celldex Therapeutics 26.90 0.30 1.13% -3.76%
Clovis Oncology 0.71 0.04 5.84% -86.33%
Esperion Therapeutics 5.46 -0.05 -0.91% -72.97%
Exelixis 18.12 -0.07 -0.38% -19.40%
Genmab 2,138.00 14.00 0.66% -12.12%
Gilead Sciences 64.76 0.29 0.45% -2.04%
GlaxoSmithKline 1,738.00 -15.80 -0.90% 29.30%
Glaxosmithkline 44.08 -0.35 -0.78% 14.51%
Immunogen 3.59 -0.09 -2.45% -41.63%
Incyte Corp 77.17 1.15 1.51% -7.89%
Insmed 18.45 -0.15 -0.81% -23.67%
Karyopharm Therapeutics 5.64 -0.17 -2.93% -39.55%
Eli Lilly 323.51 10.05 3.21% 61.97%
MacroGenics 3.33 -0.10 -2.92% -89.45%
Merck & Co 93.09 0.79 0.86% 22.66%
Moderna Inc 147.65 11.85 8.73% -20.19%
Mirati Therapeutics 33.62 -24.84 -42.49% -78.02%
Nektar Therapeutics 3.56 0.10 2.89% -80.30%
Novartis 86.92 -0.90 -1.02% 8.66%
Puma Biotechnology 1.96 0 0% -81.63%
Pfizer 53.89 -0.10 -0.19% 39.14%
Regeneron Pharmaceuticals 692.57 9.13 1.34% 37.84%
Sanofi 102.28 -1.32 -1.27% 16.28%
Seattle Genetics 138.99 0.53 0.38% -8.01%
Spectrum Pharmaceuticals 0.71 0.0003 0.04% -79.25%
Sarepta Therapeutics 72.59 1.69 2.38% -5.56%
Teva Pharmaceutical Industries Ltd 2,979.00 69.00 2.37% -13.58%
Vertex Pharmaceuticals 273.80 4.15 1.54% 31.24%
Xencor 22.45 0.09 0.38% -41.64%

Indexes Price Day Year
USND 12131 390.48 3.33% -11.77%

Seattle Genetics
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.